226
Participants
Start Date
March 26, 2021
Primary Completion Date
February 17, 2023
Study Completion Date
February 17, 2023
Novel Oral Polio Vaccine Type 1 (nOPV1)
Each 0.1 mL (2 drops) dose of vaccine contains approximately 10\^6.5 CCID50.
Novel Oral Polio Vaccine Type 3 (nOPV3)
Each 0.1 mL (2 drops) dose of vaccine contains approximately 10\^6.5 CCID50.
Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1)
The Sabin mOPV1 control vaccine contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.
Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3)
the Sabin mOPV3 control vaccine contains ≥ 10\^5.8 CCID50 per 0.1 mL (2 drops) dose.
Pharmaron CPC, Inc., Baltimore
Dartmouth Hitchcock Medical Center, Lebanon
University of North Carolina Institute for Global Health and Infectious Diseases (IGHID), Chapel Hill
University of Vermont Vaccine Testing Center, Burlington
Bill and Melinda Gates Foundation
OTHER
Centers for Disease Control and Prevention
FED
Viroclinics Biosciences B.V.
INDUSTRY
The Emmes Company, LLC
INDUSTRY
PATH
OTHER